Sign for Notice Everyday    Sign Up| Sign In| Link| English|

Our Sponsors

    Receive Latest News

    Feedburner
    Share Us


    ESGO 2018 State of the Art Rare Gynaecological Cancers Conference

    View: 332

    Website https://soaconference.esgo.org/ | Want to Edit it Edit Freely

    Category oncology; gynaecology; obsteric

    Deadline: May 31, 2018 | Date: October 04, 2018-October 06, 2018

    Venue/Country: Lyon, France

    Updated: 2018-03-09 19:21:00 (GMT+9)

    Call For Papers - CFP

    The European Society of Gynaecological Oncology (ESGO) reveals the latest clinical practice and research developments in Rare Gynaecological Cancers at ESGO 2018, State of the Art Conference, a multidisciplinary congress dedicated to providing the evidence base to diagnose and manage rare gynecological cancers, up to date scientific reviews on biology, biomarkers, preservation of fertility and the latest updates of the GCIG/ESGO guidelines.

    The conference program will feature comprehensive state-of-the art summaries on specific rare cancers by world premier Gynaecological Cancers experts, as well as interactive discussions of unanswered questions and the design of future clinical trials.

    ESGO 2018 will incorporate oral and poster sessions, bringing the latest research in rare gynaecological cancers to attendees across Europe. Abstracts submissions will be open until May 31, 2018.

    Don't miss out on the opportunity to join peers and key opinion leaders in Lyon, France, October 04-06, 2018. Get a head start, visit ESGO 2018 Conference website.


    Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
    Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.